Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer

被引：3

作者：

Piotrowska, Zofia ^{[1
]}

Sequist, Lecia V. ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 03期

关键词：

ACQUIRED-RESISTANCE; INHIBITOR; HETEROGENEITY; MECHANISMS; AZD9291; MUTATIONS; THERAPY; GENE; BRAF;

D O I：

10.1016/j.jtho.2017.01.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：419 / 421

页数：3

共 50 条

[1] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
Blaquier, Juan Bautista
Ortiz-Cuaran, Sandra
Ricciuti, Biagio
Mezquita, Laura
Cardona, Andres Felipe
Recondo, Gonzalo
CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
[2] Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
Lee, Jiyun
Piotrowska, Zofia
Soo, Ross
Cho, Byoung Chul
Lim, Sun Min
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[3] Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
Pacini, Laura
Jenks, Andrew D.
Vyse, Simon
Wilding, Christopher P.
Arthur, Amani
Huang, Paul H.
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 301 - 317
[4] PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Sos, Martin L.
Koker, Miriam
Weir, Barbara A.
Heynck, Stefanie
Rabinovsky, Rosalia
Zander, Thomas
Seeger, Jens M.
Weiss, Jonathan
Fischer, Florian
Frommolt, Peter
Michel, Kathrin
Peifer, Martin
Mermel, Craig
Girard, Luc
Peyton, Michael
Gazdar, Adi F.
Minna, John D.
Garraway, Levi A.
Kashkar, Hamid
Pao, William
Meyerson, Matthew
Thomas, Roman K.
CANCER RESEARCH, 2009, 69 (08) : 3256 - 3261
[5] Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
Nakagawa, Takayuki
Takeuchi, Shinji
Yamada, Tadaaki
Nanjo, Shigeki
Ishikawa, Daisuke
Sano, Takako
Kita, Kenji
Nakamura, Takahiro
Matsumoto, Kunio
Suda, Kenichi
Mitsudomi, Tetsuya
Sekido, Yoshitaka
Uenaka, Toshimitsu
Yano, Seiji
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (10) : 2149 - 2157
[6] Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
Sullivan, Ivana
Planchard, David
FRONTIERS IN MEDICINE, 2017, 3
[7] Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Oxnard, Geoffrey R.
Paweletz, Cloud P.
Kuang, Yanan
Mach, Stacy L.
O'Connell, Allison
Messineo, Melissa M.
Luke, Jason J.
Butaney, Mohit
Kirschmeier, Paul
Jackman, David M.
Janne, Pasi A.
CLINICAL CANCER RESEARCH, 2014, 20 (06) : 1698 - 1705
[8] Generation of genetically engineered mice for lung cancer with mutant EGFR
Kim, Da-Som
Ji, Wonjun
Ha Kim, Dong
Choi, Yun Jung
Im, Kyungtaek
Lee, Chae Won
Cho, Jeongin
Min, Joongkee
Woo, Dong-Cheol
Choi, Chang-Min
Lee, Jae Cheol
Sung, Young Hoon
Rho, Jin Kyung
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 632 : 85 - 91
[9] Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
Tricker, Erin M.
Xu, Chunxiao
Uddin, Sharmeen
Capelletti, Marzia
Ercan, Dalia
Ogino, Atsuko
Pratilas, Christine A.
Rosen, Neal
Gray, Nathanael S.
Wong, Kwok-Kin
Jaenne, Pasi A.
CANCER DISCOVERY, 2015, 5 (09) : 960 - 971
[10] Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
Lee, Pei-Chih
Fang, Yueh-Fu
Yamaguchi, Hirohito
Wang, Wei-Jan
Chen, Tse-Ching
Hong, Xuan
Ke, Baozhen
Xia, Weiya
Wei, Yongkun
Zha, Zhengyu
Wang, Yan
Kuo, Han-Pin
Wang, Chih-Wei
Tu, Chih-Yen
Chen, Chia-Hung
Huang, Wei-Chien
Chiang, Shu-Fen
Nie, Lei
Hou, Junwei
Chen, Chun-Te
Huo, Longfei
Yang, Wen-Hao
Deng, Rong
Nakai, Katsuya
Hsu, Yi-Hsin
Chang, Shih-Shin
Chiu, Tai-Jan
Tang, Jun
Zhang, Ran
Wang, Li
Fang, Bingliang
Chen, Ting
Wong, Kwok-Kin
Hsu, Jennifer L.
Hung, Mien-Chie
CANCER CELL, 2018, 34 (06) : 954 - +

← 1 2 3 4 5 →